Fourth, biomarkers of non-alcoholic fatty liver disease (liver enzymes such as alanine aminotransferase, aspartate aminotransferase or γ-glutamyl transferase) are relevant risk factors for type 2 diabetes [4], [46], but were not available in our study (with the exception of γ-glutamyl transferase in S1) so that we could not include them in our cardiometabolic risk models. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.